Back to mobile site

B.Riley Reiterates Buy Rating on Zymeworks (ZYME)

January 7, 2026 5:07 AM EST Send to a Friend
B.Riley analyst Mayank Mamtani reiterated a Buy rating and $40.00 price target on Zymeworks (NASDAQ: ZYME).The analyst comments "We believe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login